首页 > 市场调查报告书 > 医疗设备

市场调查报告书

商品编码

1634158

全球流动止血剂市场 - 2025 - 2032

Global Flowable Hemostats Market - 2025 - 2032

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2024年，全球可流动止血剂市场达到8.2516亿美元，预计到2032年将达到15.2496亿美元，在2025-2032年预测期间复合年增长率为7.0%。

可流动止血剂是一种旨在帮助控制外科手术或创伤护理期间出血的医疗产品。它们透过两种关键机制的结合发挥作用，包括提供物理屏障和积极促进人体的自然凝血过程。第一种机制涉及止血材料，例如明胶，用作机械填塞。第二种机制是包含活性成分，如凝血酶，它在启动凝血级联中发挥作用。凝血酶透过将纤维蛋白原转化为纤维蛋白来加速血块的形成，形成稳定的血块，有效密封伤口。

可流动止血器的主要优点之一是其多功能性和易用性。这些产品通常呈现液体或凝胶状形式，使其易于直接涂抹到出血部位，甚至难以触及或形状不规则的伤口。它们可以适应各种伤口类型，确保有效控制出血，无论伤口深、窄或位于复杂区域。

市场动态：

驱动程式和限制

外科手术数量不断增加

全球外科手术数量的增加预计将显着推动全球可流动止血剂市场。随着全球人口老化和慢性病的盛行率上升，对手术（从常规手术到更复杂的手术）的需求持续增长。随着越来越多的人需要针对心血管疾病、癌症和骨科问题进行手术干预，在这些手术过程中有效控制出血的需求变得更加重要。例如，美国国立卫生研究院在 2023 年表示，每年进行近 40 万例 CABG 手术，使其成为最常进行的主要外科手术。可流动止血器在这种情况下特别有价值，因为它们提供了快速可靠的止血解决方案，这对于确保患者安全和改善手术结果至关重要。

此外，根据世界卫生组织2023年的报告，每年约有119万人因道路交通事故死亡。道路交通伤害是 5-29 岁儿童和年轻人死亡的主要原因，出血占可预防死亡的很大一部分，凸显了可流动止血剂在创伤护理和外科干预中的关键作用。

可流动止血剂成本高

可流动止血剂，特别是含有特殊材料或活性成分（如凝血酶）的高级版本，往往比传统的控制出血方法（如纱布、海绵或手动压迫）更昂贵。这种成本差异可能会使医疗保健提供者不愿意采用可流动止血剂，特别是在成本效益是关键考虑因素的情况下。在预算有限的医院或诊所，这些产品的高成本可能会导致人们倾向于选择更便宜的替代品，即使流动止血剂在速度和有效性方面具有卓越的性能。

Flowable hemostats are medical products designed to help control bleeding during surgical procedures or trauma care. They work through a combination of two key mechanisms which include providing a physical barrier and actively promoting the body's natural clotting process. The first mechanism involves a hemostatic material, such as gelatin, which serves as a mechanical tamponade. The second mechanism is the inclusion of an active component, like thrombin, which plays a role in initiating the clotting cascade. Thrombin accelerates the formation of a blood clot by converting fibrinogen into fibrin, creating a stable clot that effectively seals the wound.

One of the key advantages of flowable hemostats is their versatility and ease of use. These products are typically in a liquid or gel-like form, making them easy to apply directly to bleeding sites, even in difficult-to-reach or irregularly shaped wounds. They can conform to various wound types, ensuring effective bleeding control, whether the wound is deep, narrow, or located in a complex area.

Market Dynamics: Drivers & Restraints

Increasing number of surgical procedures

The increasing number of surgical procedures worldwide is expected to significantly drive the global flowable hemostats market. As the global population ages and the prevalence of chronic conditions rises, the demand for surgeries, ranging from routine procedures to more complex operations continues to grow. With more people needing surgical interventions for conditions like cardiovascular disease, cancer, and orthopedic issues, the need for effective bleeding control during these procedures becomes even more critical. For instance, the National Institute of Health in 2023 stated that almost 400,000 CABG surgeries are performed each year making it the most commonly performed major surgical procedure. Flowable hemostats are especially valuable in this context because they provide a fast and reliable solution to stop bleeding, which is essential for ensuring patient safety and improving surgical outcomes.

Moreover, according to the World Health Organization report in 2023, approximately 1.19 million people die each year as a result of road traffic crashes. Road traffic injuries are the leading cause of death for children and young adults aged 5-29 years with hemorrhage accounting for a significant portion of preventable deaths, underscoring the critical role of flowable hemostats in trauma care and surgical interventions.

High costs of flowable hemostats

Flowable hemostats, particularly advanced versions that contain specialized materials or active components like thrombin, tend to be more expensive than traditional methods of controlling bleeding, such as gauze, sponges, or manual compression. This cost variation can make healthcare providers reluctant to adopt flowable hemostats, especially in settings where cost-effectiveness is a key consideration. In hospitals or clinics with limited budgets, the high cost of these products can result in a preference for cheaper alternatives, even if flowable hemostats offer superior performance in terms of speed and effectiveness.

Segment Analysis

The global flowable hemostats market is segmented based on product, material, application, end-user, and region.

Product:

Active Hemostats segment is expected to dominate the global Flowable Hemostats share

Active hemostats hold a dominant share of the flowable hemostats market due to their ability to directly boost the body's natural clotting process. These products contain bioactive substances, such as thrombin, that accelerate the formation of a stable blood clot by converting fibrinogen into fibrin. This makes active hemostats much more effective at controlling bleeding compared to passive hemostats, which only work through mechanical methods like pressure or absorption.

The strong market presence of active hemostats is also driven by their versatility and superior performance. While passive hemostats are often used for minor bleeding, active hemostats are favored for more serious bleeding scenarios, especially in complex surgeries like cardiovascular, trauma, or orthopedic procedures. Innovations are being unveiled by the top players with the rising demand for active hemostats. For instance, in April 2023, Baxter International Inc. unveiled multiple new additions to its surgical portfolios at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo 2023. The innovation also includes the launch of the Floseal + Recothrom flowable hemostat.

As surgical methods become increasingly advanced and minimally invasive, the demand for products that can quickly and effectively address bleeding, even in hard-to-reach areas, continues to rise. This combination of efficiency and versatility ensures that active hemostats continue to dominate the flowable hemostats market.

Geographical Analysis

North America is expected to hold a significant position in the global Flowable Hemostats share

North America is dominant in the global flowable hemostats market due to several key factors that drive demand for advanced bleeding control solutions. The region, particularly the United States, has a highly developed healthcare infrastructure with state-of-the-art hospitals, surgical centers, and research facilities. These medical facilities often perform complex surgeries that require effective bleeding management, making flowable hemostats an essential tool. The strong healthcare system ensures that these products are widely accessible and regularly used across various surgical procedures, from routine operations to high-risk interventions.

The regulatory environment in North America, particularly with regulatory bodies like the FDA, ensures that these products meet stringent quality standards, fostering trust and encouraging their widespread adoption. Furthermore, the region is also experiencing a growing number of surgical procedures, fuelled by an aging population and the rising incidence of chronic diseases like cardiovascular conditions and cancer. For instance, according to the report published by the National Institute of Health in 2023, it is stated that approximately 600,000 hysterectomy procedures are performed annually in the United States (U.S.), making it the most common non-obstetric surgical procedure among women.

As surgeries become more frequent and complex, the demand for effective, easy-to-use hemostatic products continues to rise, further solidifying North America's dominant position in the global flowable hemostats market.

Asia Pacific is at the fastest growing pace in the global flowable hemostats market share

Asia Pacific is currently experiencing the fastest growth in the global flowable hemostats. This is due to the increasing innovation of products that help in early bleeding control. Moreover, the rising prevalence of chronic diseases and an aging population in countries like Japan and China contribute significantly to the increasing number of surgical procedures in the region. With a higher incidence of conditions such as cardiovascular diseases, cancer, and diabetes, the need for complex surgeries and effective blood management solutions is also growing. Flowable hemostats are particularly valuable in these cases due to their ability to provide quick, reliable bleeding control in both traditional and minimally invasive surgeries.

Competitive Landscape

The major global players in the flowable hemostats market include Aegis Lifesciences, Baxter, Teleflex Incorporated, Becton, Dickinson, and Company, Johnson & Johnson Services, Inc., Pfizer Inc., 3-D Matrix Medical Technology, Medcura, Ferrosan Medical Devices A/S and Delta Surgical among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Global Flowable Hemostats Market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product
3.2. Snippet by Material
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increasing number of surgical procedures
- 4.1.2. Restraints
  - 4.1.2.1. High costs of flowable hemostats
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Patent Analysis
5.5. Regulatory Analysis
5.6. SWOT Analysis
5.7. Unmet Needs

6. By Product

6.1. Introduction
- 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Product
- 6.1.2. Market Attractiveness Index, By Product
6.2. Active Hemostats*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Passive Hemostats
6.4. Combination Hemostats

7. By Material

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 7.1.2. Market Attractiveness Index, By Material
7.2. Porcine Gelatin*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Bovine Gelatin

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. General Surgery*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Cardiovascular Surgery
8.4. Orthopedic Surgery
8.5. Others

9. By End-User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 9.1.2. Market Attractiveness Index, By End-User
9.2. Hospitals*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Clinics
9.4. Diagnostic Laboratories
9.5. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.7.1. U.S.
  - 10.2.7.2. Canada
  - 10.2.7.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.7.1. Germany
  - 10.3.7.2. U.K.
  - 10.3.7.3. France
  - 10.3.7.4. Spain
  - 10.3.7.5. Italy
  - 10.3.7.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.7.1. Brazil
  - 10.4.7.2. Argentina
  - 10.4.7.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.7.1. China
  - 10.5.7.2. India
  - 10.5.7.3. Japan
  - 10.5.7.4. South Korea
  - 10.5.7.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Aegis Lifesciences*
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Baxter
12.3. Teleflex Incorporated
12.4. Becton, Dickinson, and Company
12.5. Johnson & Johnson Services, Inc.
12.6. Pfizer Inc.
12.7. 3-D Matrix Medical Technology
12.8. Medcura
12.9. Ferrosan Medical Devices A/S
12.10. Delta Surgical

LIST NOT EXHAUSTIVE